Published online before print February 17, 2003, doi: 10.1161/01.CIR.0000054611.89228.92
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1291.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure
Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)
From the Department of Medicine, Montreal Heart Institute, Montreal, Canada.
Correspondence to Jean-Claude Tardif, MD, Montreal Heart Institute, 5000 Belanger St East, H1T 1C8 Montreal, Quebec, Canada. E-mail tardifjc{at}icm.umontreal.ca
Background— Diabetes mellitus is a predictor of morbidity and mortality in patients with heart failure. The effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in patients with left ventricular dysfunction is unknown. The aim of this retrospective study was to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in the group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD).
Methods and Results— Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 
126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 391 patients enrolled at the Montreal Heart Institute, 291 were not diabetic (FPG <126 mg/dL without a history of diabetes), 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31 (22.4%) in the placebo group (P<0.0001). By multivariate analysis, enalapril remained the most powerful predictor for risk reduction of developing diabetes (hazard ratio, 0.22; 95% confidence intervals, 0.10 to 0.46; P<0.0001). The effect of enalapril was striking in the subgroup of patients with impaired FPG (110 mg/dL [6.1 mmol/L] 
FPG <126 mg/dL) at baseline: 1 patient (3.3%) in the enalapril group versus 12 (48.0%) in the placebo group developed diabetes (P<0.0001).
Conclusions— Enalapril significantly reduces the incidence of diabetes in patients with left ventricular dysfunction, especially those with impaired FPG.
Key Words: angiotensin • inhibitors • diabetes mellitus • heart failure
This article has been cited by other articles:
 |
|
 |
|
  V. Baliga and R. Sapsford Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 164 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 L. J. Tamariz, J. H. Young, J. S. Pankow, H.-C. Yeh, M. I. Schmidt, B. Astor, and F. L. Brancati Blood Viscosity and Hematocrit as Risk Factors for Type 2 Diabetes Mellitus: The Atherosclerosis Risk in Communities (ARIC) Study Am. J. Epidemiol., November 15, 2008; 168(10): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Solski and D. S. Longyhore Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors Am. J. Health Syst. Pharm., May 15, 2008; 65(10): 935 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Clerk, M. A. Vincent, E. J. Barrett, M. F. Lankford, and J. R. Lindner Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiogensin-converting enzyme inhibition Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1804 - E1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Berry, J.-C. Tardif, and M. G. Bourassa Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management J. Am. Coll. Cardiol., February 13, 2007; 49(6): 631 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Barzilay, B. R. Davis, J. A. Cutler, S. L. Pressel, P. K. Whelton, J. Basile, K. L. Margolis, S. T. Ong, L. S. Sadler, J. Summerson, et al. Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, November 13, 2006; 166(20): 2191 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The DREAM Trial Investigators Effect of Ramipril on the Incidence of Diabetes N. Engl. J. Med., October 12, 2006; 355(15): 1551 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirby Heart failure and diabetes in primary care The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 220 - 228. [Abstract] [PDF]
|
|
|
|
 |
|
 C. S. Stump, M. T. Hamilton, and J. R. Sowers Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus Mayo Clin. Proc., June 1, 2006; 81(6): 796 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thornley-Brown, X. Wang, J. T. Wright Jr, O. S. Randall, E. R. Miller, J. P. Lash, J. Gassman, G. Contreras, L. J. Appel, L. Y. Agodoa, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med, April 10, 2006; 166(7): 797 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Chu, T. Lau, P.-O. Carlsson, and P. S. Leung Angiotensin II Type 1 Receptor Blockade Improves {beta}-Cell Function and Glucose Tolerance in a Mouse Model of Type 2 Diabetes Diabetes, February 1, 2006; 55(2): 367 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abuissa, P. G. Jones, S. P. Marso, and J. H. O'Keefe Jr Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials J. Am. Coll. Cardiol., September 6, 2005; 46(5): 821 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Gillespie, C. M. White, M. Kardas, M. Lindberg, and C. I. Coleman The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes Diabetes Care, September 1, 2005; 28(9): 2261 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yusuf, J. B. Ostergren, H. C. Gerstein, M. A. Pfeffer, K. Swedberg, C. B. Granger, B. Olofsson, J. Probstfield, J. V. McMurray, and on behalf of the Candesartan in Heart Failure--Ass Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure Circulation, July 5, 2005; 112(1): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Wong, A. Shankar, R. Klein, B. E. K. Klein, and L. D. Hubbard Retinal Arteriolar Narrowing, Hypertension, and Subsequent Risk of Diabetes Mellitus Arch Intern Med, May 9, 2005; 165(9): 1060 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Padwal, S. R. Majumdar, J. A. Johnson, J. Varney, and F. A. McAlister A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 736 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendon, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology Eur. Heart J., August 2, 2004; 25(16): 1454 - 1470. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Glycemic Treatment: Control of glycemia Diabetes Care, May 1, 2004; 27(5): 1227 - 1234. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ceriello and E. Motz Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 816 - 823. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Mohlig, H. Boeing, J. Spranger, M. Osterhoff, A. Kroke, E. Fisher, M. M. Bergmann, M. Ristow, K. Hoffmann, and A. F. H. Pfeiffer Body Mass Index and C-174G Interleukin-6 Promoter Polymorphism Interact in Predicting Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1885 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Hu, J. B. Meigs, T. Y. Li, N. Rifai, and J. E. Manson Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women Diabetes, March 1, 2004; 53(3): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Padwal and A. Laupacis Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review Diabetes Care, January 1, 2004; 27(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., November 1, 2003; 8(6): 163 - 163. [Full Text] [PDF]
|
|
|
|
|
|
F. B. Hu and M. J. Stampfer Is Type 2 Diabetes Mellitus a Vascular Condition? Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1715 - 1716. [Full Text] [PDF]
|
|